177 related articles for article (PubMed ID: 8613841)
1. Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma.
Cobb MA; Husain M; Andersen BJ; al-Mefty O
J Neurosurg; 1996 Jan; 84(1):85-90. PubMed ID: 8613841
[TBL] [Abstract][Full Text] [Related]
2. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry.
Møller ML; Braendstrup O
J Neurooncol; 1997 Sep; 34(3):241-6. PubMed ID: 9258816
[TBL] [Abstract][Full Text] [Related]
3. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
4. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in intracranial glioma and meningioma.
Shih YH; Kadota Y; Sato K; Sueyoshi N; Shirai T
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Apr; 53(4):193-7. PubMed ID: 7911730
[TBL] [Abstract][Full Text] [Related]
6. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
8. Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Neurol Med Chir (Tokyo); 1995 May; 35(5):289-93. PubMed ID: 7623949
[TBL] [Abstract][Full Text] [Related]
9. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
[TBL] [Abstract][Full Text] [Related]
10. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
Ho DM; Hsu CY; Ting LT; Chiang H
Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
[TBL] [Abstract][Full Text] [Related]
12. Proliferative potential of meningiomas evaluated by proliferating cell nuclear antigen expression.
Nakabayashi H; Sakaguchi M; Katsuyama J; Hakuba A
J Neurooncol; 1995; 24(3):209-17. PubMed ID: 7595751
[TBL] [Abstract][Full Text] [Related]
13. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
14. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
15. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens.
Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H
Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072
[TBL] [Abstract][Full Text] [Related]
16. Proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in benign, atypical and malignant meningiomas.
Lee MC; Kang MW; Yang BS; Park CS; Juhng SW; Jung S; Kim JH; Kim SH; Kang SS; Lee JH
Noshuyo Byori; 1995; 12(2):133-9. PubMed ID: 8867694
[TBL] [Abstract][Full Text] [Related]
17. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
18. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
19. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas.
Zimmer C; Gottschalk J; Cervos-Navarro J; Martin H; Beil M; Jautzke G
Pathol Res Pract; 1992 Dec; 188(8):951-8. PubMed ID: 1363764
[TBL] [Abstract][Full Text] [Related]
20. Invasive meningiomas in relation to high proliferating potential.
Suwa T; Kawano N; Kameya T; Ito H; Oka H; Yada K
Noshuyo Byori; 1993; 10(1):63-7. PubMed ID: 7693228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
